$PCSA News

Last published 6d ago

6d agoPCSAProcessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireVERO BEACH, FL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company advancing differentiated
1w agoPCSAProcessa Pharmaceuticals Announces Key Leadership AppointmentsGlobeNewswireVERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company advancing differentiated
1w agoPCSAProcessa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya TherapeuticsGlobeNewswireU.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosisCompany expands pipeline through research
2mo agoPCSAProcessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireVERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for
3mo agoPCSAPROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREASGlobeNewswireAcquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the
10mo agoPCSAProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireVERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that
10mo agoPCSAProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer StudyGlobeNewswireInterim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next
10mo agoPCSAProcessa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast CancerGlobeNewswirePreliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis
1y agoPCSAProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025GlobeNewswireVERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments
1y agoPCSAProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesGlobeNewswireVERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today
1y agoPCSAProcessa Pharmaceuticals Provides Portfolio and Business UpdateGlobeNewswireSigned binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of PCS6422Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla.,
1y agoPCSAProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingGlobeNewswireHANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (the "Company"), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced
1y agoPCSAProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateGlobeNewswire$452.5 million in total milestone payments$2.5 million in near-term paymentsDouble-digit royalties on future net product sales3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) --
1y agoPCSAProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025GlobeNewswireHANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of
1y agoPCSAProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingGlobeNewswireHANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and
1y agoPCSAProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025GlobeNewswireHANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer
1y agoPCSAProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceGlobeNewswireHANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer
1y agoPCSAProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor ConferenceGlobeNewswireHANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies
1y agoPCSAProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireHANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
1y agoPCSAProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireHANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial ResultsGlobeNewswireFirst patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri's ability to deliver more SN-38 to tumors compared with either irinotecan
2y agoPCSAProcessa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast CancerGlobeNewswirePhase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define the optimal dosage
2y agoPCSAProcessa Pharmaceuticals to Participate in Investor and Industry Conferences During SeptemberGlobeNewswireHANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announces that management will be participating in the following investor and industry conferences during the month of
2y agoPCSAProcessa Pharmaceuticals Provides Product Pipeline and Financial UpdateGlobeNewswirePhase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more
2y agoPCSAProcessa Pharmaceuticals Announces Positive Preclinical Data for NGC-IriGlobeNewswireDelivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE)
2y agoPCSAProcessa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast CancerGlobeNewswireOpen-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a
2y agoPCSAProcessa Pharmaceuticals Names Russell L. Skibsted as Chief Financial OfficerGlobeNewswireHANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal CancerGlobeNewswireEight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable
2y agoPCSAProcessa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceGlobeNewswireHANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical ResearchGlobeNewswireBrings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage
2y agoPCSAProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialGlobeNewswireNGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more patients due to an
2y agoPCSAProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceGlobeNewswireHANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingGlobeNewswireHANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceGlobeNewswireHANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceGlobeNewswireHANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleGlobeNewswireHANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingGlobeNewswireHANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingGlobeNewswireHANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesGlobeNewswireNext Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration NGC-Cap was better tolerated with positive preliminary
2y agoPCSAProcessa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerGlobeNewswireFDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design
2y agoPCSAProcessa Pharmaceuticals to Effect a 1-for-20 Reverse Stock SplitGlobeNewswireHANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals to Present at the Biotech Showcase 2024GlobeNewswireHANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over CapecitabineGlobeNewswireFDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved safety, even with
2y agoPCSAProcessa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation CapecitabineGlobeNewswireFDA provides guidance on Phase 2 design and Processa to continue with pre-study activities for Phase 2 trial HANOVER, MD, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or
2y agoPCSAProcessa Pharmaceuticals to Present at the MedInvest Oncology Investor ConferenceGlobeNewswireHANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and OutlookGlobeNewswireHANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company now focused on developing the next generation of
2y agoPCSAProcessa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil ThompsonGlobeNewswireHanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson
3y agoPCSAProcessa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 AmericasGlobeNewswireHANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of
3y agoPCSAProcessa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion LeadersGlobeNewswireCompany To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Processa
3y agoPCSAProcessa Pharmaceuticals to Present at the ThinkEquity ConferenceGlobeNewswireHANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of